Junko Tanizaki1, Koji Haratani1, Hidetoshi Hayashi2, Yasutaka Chiba3, Yasushi Nakamura4, Kimio Yonesaka1, Keita Kudo5, Hiroyasu Kaneda6, Yoshikazu Hasegawa7, Kaoru Tanaka1, Masayuki Takeda1, Akihiko Ito4, Kazuhiko Nakagawa1. 1. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 2. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Electronic address: hidet31@med.kindai.ac.jp. 3. Clinical Research Center, Kindai University Hospital, Osaka-Sayama, Japan. 4. Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. 5. Department of Medical Oncology and Department of Respiratory Medicine, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan. 6. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan; Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan. 7. Department of Medical Oncology, Izumi Municipal Hospital, Izumi, Japan.
Abstract
OBJECTIVE: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. METHODS: Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C-reactive protein and lactate dehydrogenase levels. Progression-free survival, overall survival, and response rate were determined. RESULTS: Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. CONCLUSIONS: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.
OBJECTIVE: The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. METHODS: Univariable and multivariable analyses were performed retrospectively for 134 patients with advanced or recurrent NSCLC treated with nivolumab to evaluate the relationship between survival and peripheral blood parameters measured before treatment initiation, including absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count, and absolute eosinophil count (AEC), as well as serum C-reactive protein and lactate dehydrogenase levels. Progression-free survival, overall survival, and response rate were determined. RESULTS: Among the variables selected by univariable analysis, a low ANC, high ALC, and high AEC were significantly and independently associated with both better progression-free survival (p = 0.001, p = 0.04, and p = 0.02, respectively) and better overall survival (p = 0.03, p = 0.03, and p = 0.003, respectively) in multivariable analysis. Categorization of patients according to the number of favorable factors revealed that those with only one factor had a significantly worse outcome than those with two or three factors. A similar trend was apparent for patients with a programmed death 1 ligand tumor proportion score less than 50%, whereas all patients with a score of 50% or higher had at least two favorable factors. CONCLUSIONS: A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.
Authors: D C Guven; H C Yildirim; E Bilgin; O H Aktepe; H Taban; T K Sahin; I Y Cakir; S Akin; O Dizdar; S Aksoy; S Yalcin; M Erman; S Kilickap Journal: Clin Transl Oncol Date: 2021-02-14 Impact factor: 3.405